Table of Content

Executive Summary
Scope of Study
Definition
Inclusion and Exclusion Criteria

1. Global Amyotrophic Lateral Sclerosis Market: Industry Outlook
1.1 Market Overview and Ecosystem
1.2 Epidemiological Analysis of Amyotrophic Lateral Sclerosis
1.2.1 U.S.
1.2.2 EU5
1.3 Market Trends
1.4 Clinical Trials
1.4.1 By Phase
1.5 Regulatory Landscape Analysis
1.5.1 Legal Requirement and Framework in U.S.
1.5.2 Legal Requirement and Framework in E.U.
1.6 Market Dynamics
1.6.1 Impact Analysis
1.6.2 Market Drivers
1.6.3 Market Restraints
1.6.4 Market Opportunities

2. Global Amyotrophic Lateral Sclerosis Market, by Region, $Million, 2023-2035
2.1 North America
2.1.1 Key Findings
2.1.2 Market Dynamics
2.1.3 Market Sizing and Forecast
2.1.3.1 North America Amyotrophic Lateral Sclerosis Market (by Country)
2.1.3.1.1 U.S.
2.2 Europe
2.2.1 Key Findings
2.2.2 Market Dynamics
2.2.3 Market Sizing and Forecast
2.2.3.1 Europe Amyotrophic Lateral Sclerosis Market (by Country)
2.2.3.1.1 Germany
2.2.3.1.2 France
2.2.3.1.3 Italy
2.2.3.1.4 U.K.
2.3 Asia-Pacific
2.3.1 Key Findings
2.3.2 Market Dynamics
2.3.3 Market Sizing and Forecast
2.3.3.1 Asia-Pacific Amyotrophic Lateral Sclerosis Market (by Country)
2.3.3.1.1 Japan

3. Global Amyotrophic Lateral Sclerosis Market - Competitive Benchmarking and Company Profiles
3.1 Competitive Landscape
3.1.1 Key Strategies and Developments by Company
3.1.1.1 Funding Activities
3.1.1.2 Mergers and Acquisitions
3.1.1.3 Regulatory Approvals
3.1.1.4 Partnerships, Collaborations and Business Expansions
3.1.2 Key Developments Analysis
3.2 Company Profiles
3.2.1 Mitsubishi Tanabe Pharma Corporation
3.2.1.1 Company Overview
3.2.1.2 Product Portfolio
3.2.1.3 Target Customers/End Users
3.2.1.4 Key Personnels
3.2.1.5 Analyst View
3.2.2 Biogen Inc.
3.2.2.1 Company Overview
3.2.2.2 Product Portfolio
3.2.2.3 Target Customers / End Users
3.2.2.4 Key Personnels
3.2.2.5 Analyst View
3.2.3 Aquestive Therapeutics, Inc.
3.2.3.1 Company Overview
3.2.3.2 Product Portfolio
3.2.3.3 Target Customers / End Users
3.2.3.4 Key Personnels
3.2.3.5 Analyst View
3.2.4 Ionis Pharmaceuticals
3.2.4.1 Company Overview
3.2.4.2 Product Portfolio
3.2.4.3 Target Customers / End Users
3.2.4.4 Key Personnels
3.2.4.5 Analyst View
3.2.5 MediciNova
3.2.5.1 Company Overview
3.2.5.2 Product Portfolio
3.2.5.3 Target Customers / End Users
3.2.5.4 Key Personnels
3.2.5.5 Analyst View
3.2.6 AB Science
3.2.6.1 Company Overview
3.2.6.2 Product Portfolio
3.2.6.3 Target Customers / End Users
3.2.6.4 Key Personnels
3.2.6.5 Analyst View
3.2.7 Brainstorm-Cell Therapeutics
3.2.7.1 Company Overview
3.2.7.2 Product Portfolio
3.2.7.3 Target Customers / End Users
3.2.7.4 Key Personnels
3.2.7.5 Analyst View
3.2.8 Italfarmaco S.p.A.
3.2.8.1 Company Overview
3.2.8.2 Product Portfolio
3.2.8.3 Target Customers / End Users
3.2.8.4 Key Personnels
3.2.8.5 Analyst View

4. Research Methodology

List of Figures
Figure: Global Amyotrophic Lateral Sclerosis Market, Coverage
Figure: Global Amyotrophic Lateral Sclerosis Market, Key Trends, Impact Analysis
Figure: Global Amyotrophic Lateral Sclerosis Market, Competitive Landscape, January 2022- April 2025

List of Tables
Table: Global Amyotrophic Lateral Sclerosis Market, Dynamics and Impact Analysis
Table: Global Amyotrophic Lateral Sclerosis Market, Regulatory Landscape
Table: Global Amyotrophic Lateral Sclerosis Market, (by Region), $Million, 2023-2035